US2011052628A1PendingUtilityA1
Recombinant Double-Stranded RNA Phage, and Use of the Same
Est. expiryAug 20, 2022(expired)· nominal 20-yr term from priority
Inventors:David Hone
C12N 2770/36162A61K 2039/542C12N 15/86A61K 2039/55594C07K 14/005A61K 39/21C12N 2740/16122A61K 2039/543A61K 2039/523C12N 7/00C12N 2740/16134A61K 2039/545C12N 2840/203A61K 2039/57C12N 2830/002A61K 2039/5256A61K 39/07A61K 39/12C12N 2770/36143A61P 31/00C12N 2795/12043A61K 2039/64A61K 2039/54A61K 2039/53C12N 2830/55A61K 40/46A61K 40/24A61K 40/19A61K 2239/38
59
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A recombinant double stranded RNA (dsRNA) phage expresses dsRNA-encoded genes in eukaryote cells. Recombinant dsRNA phage are useful for the expression of dsRNA expression cassettes encoding passenger genes, such as, but not restricted to, vaccine antigens, bioactive proteins, immunoregulatory proteins, antisense RNAs, and catalytic RNAs in eukaryotic cells or tissues. Methods are provided to deliver recombinant dsRNA phage to eukaryotic cells and tissues, either by direct administration, formulated in lipid or polylactide-coglycolide, or by utilizing a bacterial vaccine vector.
Claims
exact text as granted — not AI-modified1 - 39 . (canceled)
40 . A method of raising an immune response in an animal, comprising providing said animal with a recombinant double stranded RNA (dsRNA) nucleocapsid with a P8 protein shell and three dsRNA segments, wherein
i) at least one of said three dsRNA segments comprises a cap independent translation enhancer (CITE) operationally linked to a passenger gene; and ii) said dsRNA nucleocapsid replicates in bacterial host cells.Join the waitlist — get patent alerts
Track US2011052628A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.